Anti-Human IL-4R alpha Recombinant Nanobody (SAA1420) (HB732013)

Name: Anti-Human IL-4R alpha Recombinant Nanobody (SAA1420)
Brand: abinScience
SKU: HB732013
Price: 126 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

20ug
50ug
100ug
1mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo

HB732013

Descripción

Anti-Human CD124/IL4R/IL-4Rα Nanobody (SAA1420) [SAA1420] (HB732013) is a alpaca monoclonal antibody detecting IL-4R-alpha in ELISA. Suitable for Human.

Reactividad de especies

Human

Aplicaciones

ELISA

Especie huésped

Alpaca

Clonalidad

Monoclonal

Isotipo

VHH-8His-Cys-tag

ID de clon

SAA1420

Objetivo

CD124, IL-4 receptor subunit alpha, IL-4-binding protein, IL-4R subunit alpha, IL-4R-alpha, IL-4RA, IL4-BP, IL4R, IL4RA, Interleukin-4 receptor subunit alpha, Soluble IL-4 receptor subunit alpha, Soluble IL-4R-alpha, Soluble interleukin-4 receptor subunit alpha, sIL4Ralpha/prot

Nivel de endotoxinas

< 10 EU/mg

Pureza

>95% as determined by SDS-PAGE.

Purificación

Purified by Nickel column.

Número de acceso

P24394

Forma

Liquid

Buffer de almacenamiento

0.01M PBS pH 7.4.

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Información de uso del producto

Aplicación	Dilución
ELISA	1:2000-1:20000

Estabilidad y almacenamiento

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Fondo

Interleukin-4 receptor subunit alpha (CD124/IL4R) is a ~89 kDa protein. Receptor for both interleukin 4 and interleukin 13. Couples to the JAK1/2/3-STAT6 pathway. The IL4 response is involved in promoting Th2 differentiation. The IL4/IL13 responses are involved in regulating IgE production and, chemokine and mucus production at sites of allergic inflammation. In certain cell types, can signal through activation of insulin receptor substrates, IRS1/IRS2. CD124 is the therapeutic target of dupilumab (Dupixent).

1. Andrews, AL. et al. (2006) The Journal of allergy and clinical immunology 118, 858-65. PMID: 17030238

Nota

For research use only.

Imágenes